Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Autoimmune polyendocrinopathy
Autoimmune polyendocrinopathy
Autoimmune polyendocrinopathy
Synonyms: APS, Autoimmune polyglandular syndrome
Synonyms: APS, Autoimmune polyglandular syndrome
Synonyms: APS, Autoimmune polyglandular syndrome
Drug discovery
712
papers
On emerging therapies
Rare endocrine diseases
Autoimmune polyendocrinopathy
Overview
Autoimmune polyendocrinopathy syndromes are rare immune-mediated disorders characterized by autoimmune destruction of multiple endocrine glands and non-endocrine organs. The two main subtypes are APS-1 (APECED), caused by AIRE gene mutations, presenting with chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency [1][6][8], and APS-2, defined by Addison's disease with autoimmune thyroid disease or type 1 diabetes [2][4]. Both involve progressive organ-specific autoimmunity requiring lifelong surveillance [4][6].
Population
Prevalence: APS-1 affects 1:90,000-200,000 globally, with higher rates in Finnish (1:25,000), Sardinian, and Iranian Jewish populations [1][7][11]. APS-2 occurs in 1:1,000-20,000 [4][14]
Onset: APS-1 manifests in childhood (<15 years), while APS-2 typically develops in adulthood [4][10]
Genetic: APS-1 shows autosomal recessive inheritance; APS-2 has polygenic risk with HLA associations [4][8][10]
Burden
High morbidity from multiorgan involvement (endocrine, hepatic, pulmonary) requiring complex care coordination [6][8]
Life-threatening adrenal/hypocalcemic crises occur in 30-40% of APS-1 patients [4][7]
Reduced life expectancy (median survival ~40s) due to sepsis, hepatic failure, or treatment complications [6][8]
Therapies
Hormone replacement: Glucocorticoids for adrenal insufficiency, calcium/vitamin D for hypoparathyroidism [1][10]
Immunosuppression: Azathioprine/mycophenolate for hepatitis/pneumonitis; rituximab for refractory cases [3][6]
Antifungals: Chronic fluconazole for candidiasis prophylaxis [1][8]
Emerging therapies: Anti-CD45RC monoclonal antibody shows preventive potential in preclinical models [3]
Categories: rare endocrine diseases
Research Papers
712 drug discovery papers about Autoimmune polyendocrinopathy. Recent publications:
712 drug discovery papers about Autoimmune polyendocrinopathy. Recent publications:
categories:
Small molecules
small molecules
2026-09-24 | Case Report: Primary aldosteronism coexisting with adrenal insufficiency in a 73-year-old woman with paradoxical hyponatremia
Introduction Primary aldosteronism (PA) and autoimmune polyglandular syndrome type 2 (APS-2) represent opposing ends of adrenal pathology—hyperfunction versus hypofunction. Their coexistence is exceptionally rare and diagnostically challenging. Case presentation A 73-year-old woman with a 30-year history of refractory hypertension and recent hyponatremia was diagnosed with PA (aldosterone-to-renin ratio 29.11, positive captopril challenge, left adrenal hyperplasia). Spironolactone controlled blood pressure but paradoxically worsened hyponatremia. Two independent circadian cortisol profiles confirmed persistently low cortisol with preserved normal rhythm (first: 118.65/100.80/50.25 nmol/L; second: 133.34/71.62/39.12 nmol/L at 08:00/16:00/00:00). In contrast, plasma ACTH levels sent to an external laboratory showed no circadian variation (08:00 7.19 pmol/L, 16:00 1.21 pmol/L, 00:00 1.68 pmol/L; reference 1.60-13.90 pmol/L). This discordance-preserved cortisol rhythmicity with absent ACTH rhythm-raised the possibility of a preanalytical artifact rather than secondary adrenal insufficiency, although this inference could not be definitively proven. Physical examination revealed skin hyperpigmentation, and her history of Hashimoto’s thyroiditis supported a clinically probable diagnosis of APS-2 (clinically probable Addison’s disease with autoimmune thyroid disease), given the absence of confirmatory 21-hydroxylase antibody testing and ACTH-stimulation testing. Intervention and outcomes Prednisone 5 mg daily was added to her regimen of spironolactone and levothyroxine. Her symptoms resolved, and serum sodium normalized. Conclusion This report describes a rare case of primary aldosteronism occurring in the setting of clinically probable APS-2. The discordant cortisol-ACTH pattern serves as a critical reminder that ACTH is highly labile; clinicians must interpret results holistically, integrating clinical context and circadian patterns, and remain mindful of diagnostic uncertainty when confirmatory assays cannot be completed.
2026-07-16 | Approach to the patient with APS-1/APECED.
Autoimmune polyendocrine syndrome type 1 (APS-1), also known as Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a monogenic disorder of impaired central immune tolerance classically inherited in an autosomal recessive manner and caused by biallelic deleterious variants in the autoimmune regulator (AIRE) gene, leading to chronic mucocutaneous candidiasis (CMC) and multiorgan autoimmunity. Although hypoparathyroidism and adrenal insufficiency are among the most common and clinically consequential manifestations, it is increasingly recognized that several non-endocrine features - including autoimmune enteritis, urticarial eruption (termed APECED rash), enamel hypoplasia, autoimmune pneumonitis, and autoimmune hepatitis - often precede classical endocrinopathies, contributing to delayed diagnosis. Endocrinologists are often among the first specialists to encounter these patients and play a central role in early recognition and longitudinal care. Here we present five cases that illustrate the expanding clinical spectrum of APS-1, novel genetic mechanisms, key diagnostic challenges, and emerging therapeutic approaches. These cases highlight the importance of applying expanded clinical criteria and recognizing the limitations of standard genetic testing, including the need to consider deep intronic and dominant-negative AIRE variants. Finally, evolving mechanistic insights have established APS-1 as an interferon-γ (IFN-γ)-driven disease, providing a rationale for emerging targeted immunomodulatory therapies such as Janus kinase (JAK) inhibition with ruxolitinib. Early diagnosis enables proactive surveillance and may allow timely initiation of disease-modifying treatment.
2026-07-15 | The autoimmune regulator (AIRE) is a target of the E3-Ubiquitin ligase Seven-in-absentia homolog 1 (SIAH1).
The autoimmune regulator (AIRE) is expressed in medullary thymic epithelial cells (mTECs) and is crucial for generating an immunocompetent T cell repertoire during central tolerance. Loss of AIRE function causes autoimmune polyglandular syndrome type 1 (APS-1), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Intracellular proteins are regulated by ubiquitination pathways. E3 ubiquitin ligases are specific proteins that confer selectivity to polyubiquitination, tagging proteins for proteasomal degradation while also performing other functions. In mTECs, peptides generated via the class I antigen-processing pathway are presented by HLA-I molecules to CD8 thymocytes to eliminate self-reactive T-cell precursors. AIRE induces promiscuous gene expression in mTECs, but little is known about the regulatory mechanisms of AIRE. Previously, we and others demonstrated that AIRE is an apoptosis inductor. Here, we demonstrate that AIRE increases the intracellular levels of SIAH-interacting protein (SIP), an adaptor protein of the SIAH E3 ubiquitin ligase family. We also show that AIRE interacts with SIAH1 in the human thymus. While AIRE contains two putative SIAH-interacting motifs, it interacts with SIAH proteins only through the sequence spanning residues 119-125. AlphaFold modeling indicated that the interaction between AIRE and SIAH1 is highly analogous to that observed between SIP and SIAH1, suggesting that both proteins compete for SIAH1 binding. The CARD domain and the SIAH-interacting motif is required to AIRE-mediated apoptosis. AIRE co-localized with SIAH proteins in the cytoplasm of HEK-293 cells. Finally, SIAH1 ubiquitinated AIRE, targeting it for proteasomal degradation. Collectively, these findings reveal a novel pathway for the degradation and regulation of AIRE.
2026-05-03 | Assessment of levothyroxine sodium absorption: The possibility of ruling out malabsorption in a patient with autoimmune polyglandular syndrome
This article presents a complex clinical case of a 26-year-old female patient with autoimmune polyglandular syndrome type 2, comprising type 1 diabetes mellitus, primary adrenal insufficiency, and autoimmune thyroiditis with severe decompensated hypothyroidism (thyroid stimulating hormone 491.84 mU/L) despite treatment with high doses of levothyroxine sodium (L-T4) – 350 mcg/day. The key diagnostic challenge was to differentiate true L-T4 malabsorption from pseudomalabsorption caused by polypharmacy, non-adherence to the medication regimen, and psychosomatic disorders. To verify the cause, an L-T4 absorption test was performed using a 600 mcg dose of L-T4, with monitoring of free thyroxine (fT4) levels. The test results demonstrated an adequate increase in fT4 of more than 240% over 6 hours, which allowed for the exclusion of true malabsorption. Based on these findings, a comprehensive therapy correction was implemented: the sequence of drug administration was optimized (L-T4 to be taken strictly on an empty stomach with a subsequent interval before taking other medications), the glucocorticoid dose was reduced, insulin therapy was adjusted, and psychotherapeutic support was prescribed. This case highlights the critical importance of objectively assessing L-T4 absorption in patients with polyendocrinopathies to select the optimal pathway for achieving hypothyroidism compensation and to develop a personalized management plan.
2026-05-01 | Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
Background Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is an inborn error of immunity caused by loss-of-function of the AIRE gene. Lack of AIRE impairs thymic negative selection of T cells, causing multiorgan autoimmunity, making APECED a prototypical disease for failed central tolerance. IFNγ secreted by T cells drives inflammation in APECED, and targeting IFNγ downstream signaling with JAK1/2 inhibitor ruxolitinib remits autoimmunity in the patients. How JAK inhibition affects tissue-specific responses at the single-cell level remains unclear. Methods In longitudinal samples from four APECED patients treated with ruxolitinib on a phase-II clinical trial at National Institutes of Health, we combined single-cell RNA sequencing (scRNAseq) from blood, enteritis-affected duodenum, and scalp skin affected by alopecia with serum proteome, autoantibody microarray, and metabolome to characterize tissue-specific autoimmune responses and their normalization upon JAK inhibition. Results In tissues affected by autoimmunity, we detected multifaceted cross talk between immune and stromal cells, ushering IFNγ-driven inflammation. Ruxolitinib downregulated expression of tissue-homing chemokines and antigen presentation by stromal cells and resulted in decreased accumulation of immune cells to the tissues, as well as dampening of pro-inflammatory responses. Normalization of tissue homeostasis ensued; for example, hair keratinocytes became detectable, aligning with clinical hair regrowth. Many of the transcriptional tissue changes were discernible by the serum proteome, and the treatment response was apparent in rejuvenation of proteome-based organ age. However, treatment was also associated with subclinical proteomic changes reflecting potential side effects of JAK inhibitors, including anemia, weight gain, and hypercoagulability. We expanded the proteome evaluation to 89 additional APECED patients affected by autoimmunity, identifying a patient cluster with the most severe clinical phenotype, highest autoantibody burden, and proteome-based premature aging of multiple organs. These patients had a distinct inflammatory profile, which, in addition to excess IFNγ, was characterized by heightened IL6 responses and TGFβ resistance, partly driven by alterations in sex hormone production. Conclusions Multiomic characterization of treatment response to JAK inhibition uncovers pathogenesis and normalization of tissue-specific autoimmunity. JAK inhibitors are increasingly used to target various immune pathways in inborn errors of immunity, and understanding their complex effects systemically and in the tissues is a prerequisite for safe and successful therapy.
proteins
2026-08-01 | EP231 - ECE_2233 - Autoimmune polyendocrine syndrome type 1 caused by a momozygous aire mutation: report of two siblings
Abstract Introduction APS-1 (Autoimmune Polyendocrine Syndrome type 1) or APECED (Autoimmune Polyendocrinopathy–Candidiasis–Ectodermal Dystrophy) is a rare disease caused by biallelic genetic changes in the AIRE gene. The three most common clinical manifestations are chronic mucocutaneous candidiasis, hypoparathyroidism, and primary adrenal insufficiency (Addison's disease). More than 126 different mutations in the AIRE gene have been described. There is no clear genotype–phenotype correlation. A wide variability in the spectrum and severity of clinical manifestations has been described even among carriers with the same AIRE genetic change, even among siblings. We present the cases of two siblings (an older sister, 20 years old, and a younger brother, 17 years old) with a homozygous loss-of-function mutation in the AIRE gene. Case presentation The older sister was initially diagnosed at 6.5 years old with hypoparathyroidism and at 8 years with primary adrenal insufficiency. At 11 years, she remained at Tanner stage I, and biochemical evaluation revealed primary hypogonadism. She developed onychomycosis at 12 years and was also diagnosed with hypothyroidism at 16 years. The younger brother developed onychomycosis before the age of 9. At 9 years old, he was diagnosed with hypoparathyroidism and Addison's disease. He was also diagnosed with hypothyroidism at 10 years old. At the latest biochemical evaluation, at 17 years old, his gonadotropin levels showed an increasing trend indicative of primary gonadal insufficiency. Genetic testing revealed a homozygous AIRE variant, c.892G > A (p.Glu298Lys) in both siblings, while their parents were found to be heterozygous carriers. Conclusions Despite the well-known poor genotype–phenotype correlation in patients carrying the same pathogenic AIRE variants, herein, we describe two siblings with the same homozygous AIRE mutation who exhibited similar clinical manifestations, albeit with disease onset at different ages. Moreover, in the older sister, a switch from conventional therapy to palopegteriparatide was initiated upon reaching adulthood because of poorly controlled hypoparathyroidism.
2026-08-01 | EP593 - ECE_3589 - Therapeutic challenges of immune checkpoint inhibitor-induced type 1 diabetes within polyendocrinopathy: two case reports
Abstract Immune checkpoint inhibitors (ICIs) are increasingly used, highly effective antineoplastic agents that can induce a broad spectrum of immune-mediated endocrine adverse events involving multiple glands. Among these, hypophysitis, autoimmune thyroiditis and primary adrenal insufficiency are the most frequently reported entities, occurring either in isolation or as part of complex polyendocrinopathies. Development of endocrine toxicities has been associated with improved cancer outcomes, yet autoimmune insulitis with new-onset type 1 diabetes mellitus (T1DM) remains a relatively rare but clinically demanding complication. This abstract presents two patients treated with combined anti-CTLA-4 and anti-PD-1 therapy who developed ICI-induced T1DM as the first immune-mediated endocrine event, followed by additional endocrinopathies, creating major challenges in glycaemic management. The first case is a 52-year-old man with stage IV malignant melanoma treated with ipilimumab plus nivolumab. Before the fourth treatment cycle, routine testing revealed asymptomatic but marked hyperglycaemia without ketoacidosis. Under multiple daily human insulin injections, glycaemic control initially stabilised, allowing ambulatory follow-up. Within one month, he was additionally diagnosed with adrenal insufficiency and hypothyroidism, necessitating glucocorticoid and levothyroxine replacement. Concomitant hormone substitution was accompanied by highly labile glycaemia at home, prompting transition to analogue basal–bolus insulin therapy. On maintenance nivolumab, his melanoma exhibits substantial regression and glucose control is acceptable, although he repeatedly declines insulin pump therapy and continuous glucose monitoring. The second case is a 55-year-old woman with malignant pleural mesothelioma who also received ipilimumab plus nivolumab. Following the second cycle, severe multisystem immune-related toxicity with prominent urticarial manifestations led to discontinuation of immunotherapy. She was subsequently admitted repeatedly for diabetic ketoacidosis and painful oesophageal candidiasis. Under empiric systemic glucocorticoid treatment, glycaemic control proved extremely unstable with frequent hypoglycaemic episodes, which improved after tapering and switching methylprednisolone to hydrocortisone in the absence of clear clinical adrenal insufficiency. Autoimmune thyroiditis with hypothyroidism was diagnosed and treated with levothyroxine, while an ACTH stimulation test off steroids ultimately excluded primary adrenal insufficiency. Because of severely impaired metabolic control (HbA1c 11.6%), she was transitioned to analogue basal–bolus insulin in an inpatient setting, resulting in marked attenuation of glucose excursions and resolution of hypoglycaemia, though further basal insulin titration and planned CGM are required. These cases illustrate that ICI-induced T1DM, particularly when embedded in evolving polyendocrinopathy, demands intensive, dynamically adjusted insulin therapy and close interdisciplinary follow-up to balance oncological benefit and endocrine safety.
2026-08-01 | EP245 - ECE_2602 - Teriparatide as an effective treatment for refractory hypocalcemia in Autoimmune Polyglandular Syndrome Type 1
Abstract Introduction Autoimmune Polyglandular Syndrome Type 1 (APS-1) is a rare inherited disorder characterized by the triad of chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency. Management of hypocalcemia in APS-1 can be challenging, particularly when malabsorption limits oral calcium and active vitamin D efficacy. Teriparatide, a recombinant PTH (1-34) analog, is not approved for hypoparathyroidism but has been used off-label in selected refractory cases. Case report Female, 26-year-old, followed in the Endocrinology Department since age 18 for APS-1, comprising primary adrenal insufficiency, primary hypoparathyroidism, premature ovarian insufficiency, autoimmune hepatitis, ectodermal dystrophy of dental enamel and nails, and exocrine pancreatic insufficiency. She was on calcium, calcitriol, azathioprine, hydrocortisone, fludrocortisone, estradiol, progesterone, and pancreatin. Since 2017, she has experienced recurrent episodes of symptomatic hypocalcemia despite high-dose calcitriol (2,25 µg/day) and calcium carbonate (4500 mg/day), typically triggered by diarrheal exacerbations. She reported a long-standing history of alternating diarrhea and constipation. In 2024, she presented to the Emergency Room with facial and extremities paresthesias and muscle stiffness. One month earlier, she started complaining of nausea, vomiting, and diarrhea, and the subsequent symptomatic hypocalcemia was treated with intravenous calcium gluconate(IV calcium) and increased oral calcium dose. At readmission, biochemical evaluation revealed hypokalemia, hypocalcemia, hypomagnesemia and normal serum phosphorus, and she started IV calcium and electrolyte correction. During the first 15 days of hospitalization, repeated attempts to discontinue IV calcium and maintain oral therapy alone resulted in recurrent severe hypocalcemia. On day 16, teriparatide 20 µg once daily was initiated as an off-label treatment for refractory and severe hypocalcemia. Within two days, IV calcium supplementation was successfully discontinued, and the patient transitioned to oral therapy, with diarrhea resolution. Following discharge, oral calcium carbonate and calcitriol doses were progressively reduced. Ten months later, she remains clinically stable with normal calcium, phosphorus, and calciuria on calcium carbonate 3000 mg/day, calcitriol 1 µg/day, and teriparatide 20 µg every other day. Conclusions This case supports the use of teriparatide as a potential therapeutic option for refractory hypocalcemia due to hypoparathyroidism in APS-1, especially when malabsorption limits conventional therapy. It should be reserved for selected patients under close monitoring. However, the optimal treatment duration remains uncertain, as long-term safety data are still limited.
2026-07-17 | Palopegteriparatide Treatment for Hypoparathyroidism in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy - a Case Series and Literature Update
Abstract Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), also known as autoimmune polyglandular syndrome type 1 (APS-1), is an autosomal recessive disorder of thymic T cell negative selection that results in autoimmune destruction of various endocrine and extra-endocrine tissues. The classic clinical triad of the syndrome includes hypoparathyroidism (hypoPT), chronic mucocutaneous candidiasis (CMC), and adrenal insufficiency, while involvement of thyroid, pancreas, gonads, and ectodermal tissues are also frequently observed. Historically, treatment for hypoPT, the most common endocrine manifestation of APECED, has posed a unique challenge. Conventional therapy with oral calcium and active vitamin D analogues is often complicated by the presence of malabsorption and esophageal disorders, which are prevalent in APECED patients. Moreover, supplementation with oral calcium and active vitamin D analogues without correction of the underlying parathyroid hormone (PTH) insufficiency can result in renal and other soft-tissue calcifications. Short-acting PTH therapies, which have been used off-label in the treatment of hypoPT, fail to mimic normal parathyroid physiology due to their brief half-lives and can result in fluctuations of serum calcium levels between hypocalcemia and hypercalcemia. Long-acting PTH analogues have recently been developed to more closely mimic physiologic PTH activity. One such agent, palopegteriparatide, a prodrug of PTH (1,34), has shown promise to be the first hormone replacement therapy for hypoPT. We report our experience in four patients with APECED-associated hypoPT who initiated treatment with palopegteriparatide and were followed over the subsequent 4-15 month period. We observed a robust calcemic response to treatment during this follow-up window with wide fluctuations in serum calcium during this period of dose titration. These early observations highlight the effectiveness of palopegteriparatide in patients with APECED, enabling the discontinuation of oral calcium and active vitamin D supplements. They also highlight the question of whether etiology-specific differences in responsiveness may influence dose requirements and calcemic stability.
2026-01-01 | Refractory hypoparathyroidism in paediatric autoimmune polyglandular syndrome type 1: successful long-term use of teriparatide
Autoimmune polyglandular syndrome type 1 (APS-1) is a rare monogenic disorder caused by pathogenic variants in the autoimmune regulator (AIRE) gene.It typically manifests in childhood with at least two features of the classic triad: chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency.We present the case of an 11-year-old girl from a consanguineous family, with severe hypocalcaemia and chronic oral candidiasis.Despite high-dose calcium and calcitriol therapy, she experienced recurrent symptomatic hypocalcaemia requiring multiple hospitalisations.Genetic testing confirmed homozygosity for the pathogenic AIRE variant c.967_979del, establishing the diagnosis of APS-1.Due to poor biochemical control, teriparatide (parathyroid hormone, PTH ) was initiated at 20 µg twice daily, leading to rapid improvement in calcium-phosphate homeostasis, a 75% reduction in oral calcium requirements, and no further hospitalisations over a two-year period.The therapy was well tolerated with no adverse events.This is the first paediatric case reported in Colombia using recombinant PTH (1-34) for APS-1-related hypoparathyroidism, supporting its therapeutic role in refractory cases.
antibodies
2026-04-10 | Retinopathy caused by a primary immune regulatory disorder - the spectrum of AIRE-associated retinopathy: case series and literature review.
Retinal involvement in autoimmune polyendocrine syndrome type 1 (APS1), a rare monogenic autoimmune disorder caused by mutations in the AIRE gene, is increasingly recognised but remains poorly defined. Prior reports suggest a variable phenotype, ranging from mild changes to severe vision loss, often presumed untreatable. We explored the range of retinal phenotypes associated with AIRE gene deficiency in a multicentre case series of patients with APS1. We performed a retrospective case note review of patients with molecularly confirmed APS1 from tertiary ophthalmic centres. Clinical history, multimodal retinal imaging, electrophysiology, genetic data, and treatment regimens were analysed. Histopathology was available in one case postmortem. Records were reviewed from five unrelated female patients. Median age was 14 years at onset of ocular involvement and 33 years at most recent follow up. Some findings from two cases have been previously reported. Three distinct pathogenic AIRE variants contributing to biallelic genotypes were observed. Retinal findings ranged from structurally and functionally normal to advanced degeneration. One patient demonstrated sharp zonal atrophy on histopathology. Inflammatory features predominated in two cases, both showing durable vision preservation with periocular or systemic immunomodulation. One patient demonstrated four years of disease stabilisation with rituximab. No consistent genotype-phenotype correlation emerged. AIRE-associated retinopathy encompasses a diverse spectrum, from clinically silent to profound degeneration. Early, targeted immunomodulation might preserve vision in selected cases. These findings advocate for ophthalmic surveillance in APS1, and support further investigation into predictive biomarkers and possible tailored immunotherapy in this vision-threatening autoimmune disorder.
2026-02-07 | Pediatric IPEX-Associated Dermatitis Responds To Dupilumab: Evidence from Skin Transcriptomics and Immune Profiling.
Immunodysregulation, Polyendocrinopathy, Enteropathy, and X-linked (IPEX) syndrome is a rare autoimmune disorder caused by mutations in the FOXP3 gene. Patients with IPEX frequently present with severe dermatitis, diabetes, and enteropathy. This study explores the efficacy of Dupilumab (an anti-IL-4Rα monoclonal antibody) in treating persistent, severe dermatitis in an IPEX patient refractory to conventional treatments like sirolimus. We conducted a clinical case study of a 2-year-old IPEX patient with refractory dermatitis. Whole-exome sequencing (WES) confirmed the FOXP3 mutation. Skin biopsies were analyzed for inflammatory gene expression by RNA sequencing and immunohistochemistry to characterize inflammatory pathways. Immune cell phenotyping was performed using flow cytometry pre- and post-treatment in peripheral blood mononuclear cells (PBMCs). The patient was treated with Dupilumab alongside sirolimus and prednisone. Clinical improvements were evaluated using the Eczema Area and Severity Index (EASI) score. Immunohistochemistry revealed elevated IL-13 expression. RNA sequencing of skin samples revealed upregulation of both Th1- and Th2-related genes, suggesting a dual inflammatory phenotype in IPEX dermatitis. The patient exhibited significant clinical improvement after 8 months of sustained Dupilumab therapy, with the EASI decreasing from 24.8 to 0.4. Flow cytometry demonstrated a reduction in Th1 and Th2 cell subsets post-treatment, accompanied by an increase in Treg and Th3 cell populations as well as enhanced expression of immunosuppressive markers such as CTLA-4 and CD39. Dupilumab appears promising as a therapeutic option for managing refractory dermatitis in IPEX, particularly by attenuating Th1/Th2 inflammation and promoting regulatory responses mediated by Treg and Th3 cells.
2025-12-22 | CARD8: An Emerging Genetic Cause of Autoinflammatory and CVID-Like Syndromes?
Introduction CARD8 encodes the caspase recruitment domain-containing protein 8, a negative regulator of the NLRP3 inflammasome and a modulator of innate immune signaling. Although not yet formally classified among inborn errors of immunity (IEIs), emerging evidence suggests a potential role of CARD8 variants in autoinflammatory syndromes and immune dysregulation. Case Presentations We describe three unrelated patients from different families with variable phenotypes involving autoinflammation and immune dysregulation. Patient 1: A 15-year-old female with an IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked)-like phenotype, including alopecia universalis, growth retardation, pubertal delay, and elevated serum IL-18 levels. A heterozygous frameshift variant in CARD8 (c.40delG, p.Glu14fs) was identified. Patient 2: A 3-year-old male presenting with neonatal lupus-like rash, severe atopic dermatitis, refractory autoimmune cytopenias, persistent hepatitis, and total villous atrophy on intestinal biopsy (Marsh 3b). A heterozygous frameshift variant (c.68dupG, p.Ser24fs) was detected. Patient 3: A 42-year-old female with adult-onset CVID (common variable immunodeficiency)-like phenotype, including recurrent pneumonia, chronic diarrhea, and persistent hypogammaglobulinemia requiring immunoglobulin replacement. A heterozygous missense variant (c.1093A>C, p.Met365Leu) was identified. Discussion These cases illustrate the broad clinical spectrum associated with CARD8 variants, ranging from severe early-onset autoinflammatory disease to adult-onset humoral immunodeficiency. The presence of elevated IL-18 and multi-organ involvement supports dysregulated inflammasome activation as a key pathogenic mechanism. Importantly, heterozygous variants may result in incomplete penetrance and variable expressivity, complicating diagnosis and counseling. Conclusion CARD8 mutations should be considered in patients presenting with unexplained autoinflammation, immune dysregulation, or CVID-like phenotypes. Recognition of this spectrum may facilitate earlier diagnosis, appropriate therapeutic interventions targeting IL-1/IL-18 pathways, and genetic counseling for affected families.
2025-11-12 | Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1.
Autoimmune polyendocrine syndrome type 1 (APS-1) is a rare, monogenic autoimmune disorder that may manifest as type 1 diabetes (T1D). Teplizumab, an anti-CD3 monoclonal antibody, delays progression of stage 2 T1D, but its effects in APS-1-associated diabetes are unknown. We report clinical responses of two adolescents with APS-1 and stage 2 T1D who received 14-day courses of teplizumab. In one patient, pancreatic MRI and spectral immune cell phenotyping were performed before and after treatment. Both patients exhibited improved glycemia. One who briefly required insulin recovered insulin independence 2 weeks after therapy. Pancreatic volume transiently increased, and circulating lymphocytes showed changes in homing receptors and senescence markers in the individual who underwent those studies. Nonpancreatic APS-1 manifestations were unchanged. Teplizumab may preserve β-cell function in APS-1-associated T1D. Larger studies are needed to define efficacy, durability, and immunologic and tissue mechanisms in this rare context.
2025-11-01 | First-in-class anti-human CD45RC antibody targets CD45RChigh T and B cells to mitigate pathogenic immune responses.
CD45RC, an isoform of the transmembrane tyrosine phosphatase CD45, regulates T and B cell antigen receptor signaling and is highly expressed on Th1 precursors, Th1 cells, T effector memory CD45RA+ cells, and most B cells. Preclinical studies have shown that anti-CD45RC monoclonal antibodies (mAbs) can prevent or control diseases such as transplant rejection, graft-versus-host disease (GvHD), Duchenne muscular dystrophy (DMD), and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED or APS-1). However, their mechanism of action remained unclear. Here, we elucidate the mechanism of anti-human CD45RC mAbs, showing that it selectively induces apoptosis in CD45RChigh T and B cells through binding to cells expressing >24 CD45RC molecules/μm2. This interaction triggers intracellular signaling without cytokine release. Cytotoxicity by apoptosis is enhanced by crosslinking with a secondary antibody. The mAb also promotes antibody-dependent cellular phagocytosis by monocyte-derived macrophages, without inducing antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, likely due to the length of CD45RC. In CD34+-humanized NSG mice, anti-CD45RC mAbs demonstrated dose-dependent depletion of CD45RChigh T and B cells and defined a minimum effective dose to prevent xenogeneic GvHD. These findings define the mechanism of action of this first-in-class anti-human CD45RC therapeutic mAb and supports its potential for the treatment of transplant rejection, GvHD, and autoimmune diseases.
cell therapies
2026-09-07 | Distinguishing clinical features of paediatric autoimmune Addison's disease and polyendocrine syndromes: a 15-year single-centre observational study from Baghdad, Iraq.
Autoimmune Addison's disease (AAD) is a rare endocrine disorder characterised by immune-mediated destruction of the adrenal cortex. AAD may occur in isolation or as part of a broader autoimmune polyendocrine syndrome (APS). Distinguishing the two is essential owing to implications for patient screening and prognosis. Earlier identification of APS patients is crucial for preserving residual adrenal function and developing future targeted therapies. This study aimed to define clinical and laboratory features of paediatric isolated AAD and APS. This retrospective cohort study recruited 55 paediatric patients; 27/55 had isolated AAD and 28/55 had APS. They were followed at the Children's Welfare Teaching Hospital, Baghdad, Iraq, between 2009 and 2024. Data collected and compared included: demographic variables (age, gender, family history, duration of symptoms), presenting clinical features and adrenal crisis, and laboratory parameters. Male predominance was observed in both groups, although the difference was not significant. Positive family history was more frequent in APS (p = 0.03). Clinically, hyperpigmentation, weight loss, poor appetite, and hypoglycaemia-induced seizures were significantly higher in isolated AAD (p = 0.0001, 0.0002, 0.042, 0.041). Adrenal crises were more frequent in APS cases (p = 0.18). Major risk factors for adrenal crisis included poor treatment compliance and infections. Laboratory parameters showed that hyperkalaemia and hypoglycaemia were significantly more pronounced in AAD (0.0079 and 0.00002). Distinguishing isolated AAD from APS may be clinically useful. Differences were observed in metabolic severity, family history, weight loss, hyperpigmentation, and risk of adrenal crisis. These findings suggest that management of both conditions may benefit from a tailored approach, emphasizing treatment adherence and infection prevention in both groups.
2026-08-16 | FOXP3 as a therapeutic target in autoimmune diseases: Molecular regulation, regulatory T cells, and emerging precision immunotherapies
Forkhead box protein P3 (FOXP3) is a key transcription factor responsible for the development and function of regulatory T cells (Tregs), which play a crucial role in maintaining immune tolerance and preventing autoimmune responses. Defects in FOXP3 expression or function can impair Treg activity, leading to immune dysregulation and the development of autoimmune diseases. While complete loss of FOXP3 results in immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, altered FOXP3 expression and Treg dysfunction have also been reported in common autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes mellitus, multiple sclerosis, and inflammatory bowel disease. Recent advances have significantly improved our understanding of the molecular mechanisms regulating FOXP3, including transcriptional control, epigenetic modifications, metabolic pathways, and environmental influences that affect Treg stability and function. These discoveries have led to the development of novel therapeutic approaches aimed at restoring immune tolerance through enhancement of FOXP3 activity and Treg-mediated suppression. Strategies such as low-dose interleukin-2 therapy, adoptive Treg cell transfer, antigen-specific Treg therapy, chimeric antigen receptor regulatory T cells (CAR-Tregs), and gene-editing technologies have shown promising results in preclinical and early clinical studies. This review summarizes the current understanding of FOXP3 biology, its role in autoimmune disease pathogenesis, and recent advances in FOXP3-directed therapeutic strategies. In addition, emerging concepts including Treg plasticity, epigenetic regulation, immunometabolism, and precision immunotherapy are discussed. A better understanding of FOXP3-mediated immune regulation may facilitate the development of targeted therapies capable of achieving long-term immune tolerance and improved clinical outcomes in patients with autoimmune diseases.
2026-06-26 | FOXP3 Mutations and Instability as Determinants of Regulatory T-Cell Plasticity in Endocrine Autoimmunity
Autoimmune endocrine diseases constitute a group of disorders characterized by immune-mediated destruction or dysfunction of hormone-producing glands. The pathogenesis of these diseases reflects a breakdown of immune tolerance in which regulatory T cells (Tregs) play a key role. The transcription factor forkhead box P3 (FOXP3) is a master regulator of Treg differentiation and suppressive function. Also, it is central to maintaining self-tolerance. Genetic mutations in FOXP3, including those responsible for immune dysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) syndrome, highlight the critical role of FOXP3 in endocrine immune tolerance. Emerging evidence suggests that autoimmune endocrine disorders may reflect organ-specific destabilization of FOXP3 expression rather than complete Treg deficiency. The reversibility or irreversible loss of FOXP3 gene expression represents a key determinant of Treg plasticity and the persistence of autoimmune inflammation. This review proposes an integrated genetic–epigenetic model of FOXP3 instability and examines how the endocrine microenvironment shapes Treg plasticity. Genetic or epigenetic alterations affecting FOXP3 expression can impair Treg activity and precipitate endocrine organ-specific autoimmunity. Epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNA-mediated regulation that modulate FOXP3 transcriptional activity are discussed. From a translational perspective, the potential of FOXP3 as a biomarker for endocrine disease susceptibility and progression was summarized. Furthermore, therapeutic strategies employed for expanding or engineering functional FOXP3+ Tregs using antigen-specific vaccines, chimeric antigen receptors (CAR)-Tregs, gene therapy, or low-dose interleukin-2 (IL-2) were described.
2026-05-01 | Human FOXP3 Isoforms in Health and Disease
Forkhead box P3 (FOXP3) is the master transcription factor of regulatory T cells (Tregs) and is essential for maintaining immune tolerance. FOXP3 is stably expressed in Tregs, driving their suppressive function, and it is transiently induced in conventional T cells (Tconv) upon activation, where it fine-tunes immune responses. In humans, but not in mice, FOXP3 is expressed as two major isoforms: the full-length protein (FOXP3FL) and an isoform lacking exon 2 (FOXP3Δ2), with additional variants such as FOXP3Δ7 and FOXP3Δ2Δ7 described. The precise contribution of each isoform to Treg development, stability, and function in health and disease remains incompletely defined, although clinical observations indicate that patients expressing only FOXP3Δ2 develop autoimmunity, highlighting a nonredundant role for FOXP3FL in Treg-mediated tolerance. Multiple studies have further associated increased FOXP3Δ2 expression with autoimmune disease and reduced Treg stability, suggesting that the relative abundance of FOXP3FL and FOXP3Δ2 may critically shape Treg function and the balance between tolerance and pathology. However, the physiological expression levels and ratios of FOXP3FL and FOXP3Δ2 in Tregs and activated Tconvs remain poorly characterized, hindering understanding of the distinct functions of these isoforms, the correlation of specific FOXP3 mutations with isoform expression patterns and disease severity, and the development of Treg-targeted and gene transfer–based therapies. To address this, we quantified isoform-specific expression in Tregs and activated Tconvs from healthy donors and in patients with loss-of-function mutations in FOXP3 that cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, a severe monogenic disorder that typically presents in early infancy, affects male patients, and is almost uniformly fatal without definitive therapy. Our data indicate that FOXP3Δ2 is the dominant isoform in activated Tconvs and Tregs across both cohorts, with a FOXP3FL:FOXP3Δ2 ratio of 0.52 ± 0.08, suggesting that regulated co-expression of FOXP3 isoforms but not exclusive expression of a single isoform underpins effective Treg development and function. Consequently, therapeutic strategies for IPEX and autoimmunity should aim to restore a physiologic FOXP3 isoform balance rather than solely achieving full-length FOXP3 expression.
2026-03-15 | Preclinical efficacy and safety assessment of engineered regulatory T cells for treatment of IPEX and other autoimmune disorders.
FOXP3 is an essential transcription factor driving lineage commitment and function of regulatory T cells (Tregs). We previously reported a proof-of-concept study describing engineered Tregs (EngTregs) generated using homology-directed repair-based editing of the FOXP3 gene in CD4+ T cells, resulting in constitutive, high-level endogenous FOXP3 expression leading to acquisition of a Treg phenotype and robust in vitro and in vivo suppressive function. Here, we expand this gene-editing strategy to integrate a functional FOXP3 cDNA to enable EngTreg therapy for immune dysregulation, poly-endocrinopathy, enteropathy, X-linked syndrome (IPEX), a devastating multiorgan autoimmune disorder mediated by mutations within the FOXP3 gene. We provide a detailed characterization of preclinical EngTreg generation, including gene targeting efficiencies, cell enrichment and expansion, analyses of potential off-target editing, and phenotypic and functional characterization, including in vitro suppression of effector T cells and in vivo reversal of graft-versus-host disease. Importantly, in parallel, we utilize syngeneic and humanized mouse models to demonstrate the safety of EngTregs in primary and secondary humoral responses and viral infection control, respectively. Our combined preclinical dataset strongly supports the efficacy and safety of EngTregs as a promising potential cellular therapeutic approach for IPEX and possibly other autoimmune disorders.
other
2025-08-14 | Precision T cell correction platform for inborn errors of immunity.
CRISPR-Cas9 gene editing is a promising tool to correct pathogenic variants for autologous cell therapies targeting inborn errors of immunity (IEI). Current strategies, such as gene knockout or cDNA knockin, address many single-gene defects but can disrupt gene expression, highlighting the need for precise correction platforms. While transplanting corrected autologous hematopoietic stem cells is a curative approach, it is unsuitable for patients with advanced disease, inflammation, or acute infections. As correcting T cells is an alternative therapeutic strategy for lymphoid IEIs, we present an efficient T cell single-nucleotide variant (SNV) correction platform based on homology-directed repair (HDR). By using STAT1 gain-of-function, cartilage hair hypoplasia, deficiency of ADA2, and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy as IEI models, we demonstrate that our platform achieves up to 80% correction, with resultant functional correction of the disease phenotype in the selected models. Furthermore, we performed safety profiling using GUIDE-seq, single-cell RNA sequencing, long-read genome sequencing, and proteomics analysis and detected no genomic, transcriptomic, or proteomic aberrations. This study establishes HDR-based SNV editing as a portable method for developing clinical autologous T cell therapies and represents a promising step toward a broad-spectrum gene correction platform for treating diverse monogenic immune disorders.
2025-03-12 | The CRISPR-Cas9 System Is Used to Edit the Autoimmune Regulator Gene in Vitro and in Vivo.
Although mutations in the AIRE gene in patients with autoimmune polyendocrine syndrome type 1 (APS-1) syndrome are associated with the onset of this autoimmune disease, much of what is known about its mechanisms has been obtained through studies with Aire mutant Mus musculus mouse model or with Aire mutant medullary thymic epithelial cells (mTEC) cultured in vitro. The in vivo murine model was soon established, and ten mutant strains are currently described. Most Aire mutant mice were obtained through homologous recombination, which generated Aire knockout (KO) animals. Nevertheless, long-term cultures of mTECs from APS-1 patients or Aire mutant mice are difficult to establish. The CRISPR-Cas9 system to edit Aire in a murine mTEC line in vitro and mouse embryo has been successfully used to overcome this. The ribonucleoprotein (RNP) complexes composed of the guide RNA (gRNA), the Cas9 enzyme, and single-stranded oligonucleotides (ssODN) were designed to target Aire exons 6 and 8 separately. The CRISPR-Cas9 makes it possible to produce NHEJ-derived indels or HDR-derived mutations. Efforts are being concentrated on using RNP complex rather than plasmid vectors, as RNP makes recurrent NHEJ-derived mutations among in vitro and in vivo editions. One recurrent mutation was described in the Aire exon 6 (del 3554G) and the other in the exon 8 (del 5676_5677TG), i.e., the exon 6 mutation was kept in an mTEC clone edited in vitro and in vivo in a mouse, and the exon 8 mutation was kept in several mTEC clones in vitro. In contrast, none of the mutations obtained with the nickase system (plasmid expression vector) were recurrent, indicating the participation of the RNP complex in recurring mutation, which offers advantages, as it does not involve recombinant plasmids and does not generate a genetically modified organism but rather a mutant animal or cell.
2024-10-25 | Uncovering ASO-Targetable Deep Intronic AIRE Variants: Insights and Therapeutic Implications.
High-throughput DNA sequencing has accelerated the discovery of disease-causing genetic variants, yet only in 10-40% of cases yield a genetic diagnosis. Increased implementation of genome sequencing has enabled a deeper exploration of the noncoding genome and recognition of noncoding variants as major contributors to disease. In a recent study, we identified a deep intronic variant in the AutoImmune REgulator (AIRE) gene (c.1504-818 G>A) as the cause of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), a life-threatening monogenic autoimmune disorder most often caused by biallelic AIRE defects. This deep intronic variant disrupts normal splicing AIRE , causing pseudoexon inclusion and altered protein function. By developing an antisense oligonucleotide (ASO) targeting the pseudoexon sequence, we restored normal AIRE transcript in vitro, thereby revealing a potential genotype-specific candidate treatment. Our study illustrates key aspects of intronic variant detection, validation, and candidate ASO development. Herein, we briefly highlight the growing potential of ASO-based therapies for deep intronic variants, addressing the unmet need of personalized, genotype-specific therapies in diseases lacking curative options.
2024-09-18 | A deep intronic splice-altering AIRE variant causes APECED syndrome through antisense oligonucleotide-targetable pseudoexon inclusion.
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a life-threatening monogenic autoimmune disorder primarily caused by biallelic deleterious variants in the autoimmune regulator (AIRE) gene. We prospectively evaluated 104 patients with clinically diagnosed APECED syndrome and identified 17 patients (16%) from 14 kindreds lacking biallelic AIRE variants in exons or flanking intronic regions; 15 had Puerto Rican ancestry. Through whole-genome sequencing, we identified a deep intronic AIRE variant (c.1504-818 G>A) cosegregating with the disease in all 17 patients. We developed a culture system of AIRE-expressing primary patient monocyte-derived dendritic cells and demonstrated that c.1504-818 G>A creates a cryptic splice site and activates inclusion of a 109-base pair frame-shifting pseudoexon. We also found low-level AIRE expression in patient-derived lymphoblastoid cell lines (LCLs) and confirmed pseudoexon inclusion in independent extrathymic AIRE-expressing cell lines. Through protein modeling and transcriptomic analyses of AIRE-transfected human embryonic kidney 293 and thymic epithelial cell 4D6 cells, we showed that this variant alters the carboxyl terminus of the AIRE protein, abrogating its function. Last, we developed an antisense oligonucleotide (ASO) that reversed pseudoexon inclusion and restored the normal AIRE transcript sequence in LCLs. Thus, our findings revealed c.1504-818 G>A as a founder APECED-causing AIRE variant in the Puerto Rican population and uncovered pseudoexon inclusion as an ASO-reversible genetic mechanism underlying APECED.
2024-09-06 | T cell correction pipeline for Inborn Errors of Immunity
CRISPR/Cas9 gene editing technology is a promising tool for correcting pathogenic variants for autologous cell therapies for Inborn Errors of Immunity (IEI). The present IEI correction strategies mainly focus on the knock-in of therapeutic cDNAs, or knockout of the disease-causing gene when feasible. These strategies address many single-gene defects but may disrupt gene expression and require significant optimization for each newly discovered IEI-causing gene, highlighting the need for complementary platforms that can precisely correct diverse pathogenic variants. Here, we present a safe and efficient T cell single nucleotide variant (SNV) correction pipeline based on homology-directed repair (HDR), suitable for diverse monogenic mutations. By using founder mutations of Deficiency of ADA2 (DADA2), Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and Cartilage Hair Hypoplasia (CHH) as IEI models, we show that our pipeline can achieve up to 80% bi-allelic editing, with resultant functional correction of the disease phenotype in patient T cells. We do not find detectable pre-malignant off-target effects or karyotypic, transcriptomic or proteomic aberrations upon profiling patient T cells with GUIDE-seq, single cell RNA sequencing, PacBio based long-read whole genome sequencing, and high-throughput proteomics. This study demonstrates that HDR-based SNV editing is a safe and effective option for IEI T cell correction and that it could be developed to an autologous T cell therapy, as the presented protocol is scalable for a GMP-compatible workflow. This study is a step towards the development of gene correction platform that targets a broad number of monogenic mutations.
small molecules
2026-09-24 | Case Report: Primary aldosteronism coexisting with adrenal insufficiency in a 73-year-old woman with paradoxical hyponatremia
Introduction Primary aldosteronism (PA) and autoimmune polyglandular syndrome type 2 (APS-2) represent opposing ends of adrenal pathology—hyperfunction versus hypofunction. Their coexistence is exceptionally rare and diagnostically challenging. Case presentation A 73-year-old woman with a 30-year history of refractory hypertension and recent hyponatremia was diagnosed with PA (aldosterone-to-renin ratio 29.11, positive captopril challenge, left adrenal hyperplasia). Spironolactone controlled blood pressure but paradoxically worsened hyponatremia. Two independent circadian cortisol profiles confirmed persistently low cortisol with preserved normal rhythm (first: 118.65/100.80/50.25 nmol/L; second: 133.34/71.62/39.12 nmol/L at 08:00/16:00/00:00). In contrast, plasma ACTH levels sent to an external laboratory showed no circadian variation (08:00 7.19 pmol/L, 16:00 1.21 pmol/L, 00:00 1.68 pmol/L; reference 1.60-13.90 pmol/L). This discordance-preserved cortisol rhythmicity with absent ACTH rhythm-raised the possibility of a preanalytical artifact rather than secondary adrenal insufficiency, although this inference could not be definitively proven. Physical examination revealed skin hyperpigmentation, and her history of Hashimoto’s thyroiditis supported a clinically probable diagnosis of APS-2 (clinically probable Addison’s disease with autoimmune thyroid disease), given the absence of confirmatory 21-hydroxylase antibody testing and ACTH-stimulation testing. Intervention and outcomes Prednisone 5 mg daily was added to her regimen of spironolactone and levothyroxine. Her symptoms resolved, and serum sodium normalized. Conclusion This report describes a rare case of primary aldosteronism occurring in the setting of clinically probable APS-2. The discordant cortisol-ACTH pattern serves as a critical reminder that ACTH is highly labile; clinicians must interpret results holistically, integrating clinical context and circadian patterns, and remain mindful of diagnostic uncertainty when confirmatory assays cannot be completed.
2026-07-16 | Approach to the patient with APS-1/APECED.
Autoimmune polyendocrine syndrome type 1 (APS-1), also known as Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a monogenic disorder of impaired central immune tolerance classically inherited in an autosomal recessive manner and caused by biallelic deleterious variants in the autoimmune regulator (AIRE) gene, leading to chronic mucocutaneous candidiasis (CMC) and multiorgan autoimmunity. Although hypoparathyroidism and adrenal insufficiency are among the most common and clinically consequential manifestations, it is increasingly recognized that several non-endocrine features - including autoimmune enteritis, urticarial eruption (termed APECED rash), enamel hypoplasia, autoimmune pneumonitis, and autoimmune hepatitis - often precede classical endocrinopathies, contributing to delayed diagnosis. Endocrinologists are often among the first specialists to encounter these patients and play a central role in early recognition and longitudinal care. Here we present five cases that illustrate the expanding clinical spectrum of APS-1, novel genetic mechanisms, key diagnostic challenges, and emerging therapeutic approaches. These cases highlight the importance of applying expanded clinical criteria and recognizing the limitations of standard genetic testing, including the need to consider deep intronic and dominant-negative AIRE variants. Finally, evolving mechanistic insights have established APS-1 as an interferon-γ (IFN-γ)-driven disease, providing a rationale for emerging targeted immunomodulatory therapies such as Janus kinase (JAK) inhibition with ruxolitinib. Early diagnosis enables proactive surveillance and may allow timely initiation of disease-modifying treatment.
2026-07-15 | The autoimmune regulator (AIRE) is a target of the E3-Ubiquitin ligase Seven-in-absentia homolog 1 (SIAH1).
The autoimmune regulator (AIRE) is expressed in medullary thymic epithelial cells (mTECs) and is crucial for generating an immunocompetent T cell repertoire during central tolerance. Loss of AIRE function causes autoimmune polyglandular syndrome type 1 (APS-1), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Intracellular proteins are regulated by ubiquitination pathways. E3 ubiquitin ligases are specific proteins that confer selectivity to polyubiquitination, tagging proteins for proteasomal degradation while also performing other functions. In mTECs, peptides generated via the class I antigen-processing pathway are presented by HLA-I molecules to CD8 thymocytes to eliminate self-reactive T-cell precursors. AIRE induces promiscuous gene expression in mTECs, but little is known about the regulatory mechanisms of AIRE. Previously, we and others demonstrated that AIRE is an apoptosis inductor. Here, we demonstrate that AIRE increases the intracellular levels of SIAH-interacting protein (SIP), an adaptor protein of the SIAH E3 ubiquitin ligase family. We also show that AIRE interacts with SIAH1 in the human thymus. While AIRE contains two putative SIAH-interacting motifs, it interacts with SIAH proteins only through the sequence spanning residues 119-125. AlphaFold modeling indicated that the interaction between AIRE and SIAH1 is highly analogous to that observed between SIP and SIAH1, suggesting that both proteins compete for SIAH1 binding. The CARD domain and the SIAH-interacting motif is required to AIRE-mediated apoptosis. AIRE co-localized with SIAH proteins in the cytoplasm of HEK-293 cells. Finally, SIAH1 ubiquitinated AIRE, targeting it for proteasomal degradation. Collectively, these findings reveal a novel pathway for the degradation and regulation of AIRE.
2026-05-03 | Assessment of levothyroxine sodium absorption: The possibility of ruling out malabsorption in a patient with autoimmune polyglandular syndrome
This article presents a complex clinical case of a 26-year-old female patient with autoimmune polyglandular syndrome type 2, comprising type 1 diabetes mellitus, primary adrenal insufficiency, and autoimmune thyroiditis with severe decompensated hypothyroidism (thyroid stimulating hormone 491.84 mU/L) despite treatment with high doses of levothyroxine sodium (L-T4) – 350 mcg/day. The key diagnostic challenge was to differentiate true L-T4 malabsorption from pseudomalabsorption caused by polypharmacy, non-adherence to the medication regimen, and psychosomatic disorders. To verify the cause, an L-T4 absorption test was performed using a 600 mcg dose of L-T4, with monitoring of free thyroxine (fT4) levels. The test results demonstrated an adequate increase in fT4 of more than 240% over 6 hours, which allowed for the exclusion of true malabsorption. Based on these findings, a comprehensive therapy correction was implemented: the sequence of drug administration was optimized (L-T4 to be taken strictly on an empty stomach with a subsequent interval before taking other medications), the glucocorticoid dose was reduced, insulin therapy was adjusted, and psychotherapeutic support was prescribed. This case highlights the critical importance of objectively assessing L-T4 absorption in patients with polyendocrinopathies to select the optimal pathway for achieving hypothyroidism compensation and to develop a personalized management plan.
2026-05-01 | Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
Background Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is an inborn error of immunity caused by loss-of-function of the AIRE gene. Lack of AIRE impairs thymic negative selection of T cells, causing multiorgan autoimmunity, making APECED a prototypical disease for failed central tolerance. IFNγ secreted by T cells drives inflammation in APECED, and targeting IFNγ downstream signaling with JAK1/2 inhibitor ruxolitinib remits autoimmunity in the patients. How JAK inhibition affects tissue-specific responses at the single-cell level remains unclear. Methods In longitudinal samples from four APECED patients treated with ruxolitinib on a phase-II clinical trial at National Institutes of Health, we combined single-cell RNA sequencing (scRNAseq) from blood, enteritis-affected duodenum, and scalp skin affected by alopecia with serum proteome, autoantibody microarray, and metabolome to characterize tissue-specific autoimmune responses and their normalization upon JAK inhibition. Results In tissues affected by autoimmunity, we detected multifaceted cross talk between immune and stromal cells, ushering IFNγ-driven inflammation. Ruxolitinib downregulated expression of tissue-homing chemokines and antigen presentation by stromal cells and resulted in decreased accumulation of immune cells to the tissues, as well as dampening of pro-inflammatory responses. Normalization of tissue homeostasis ensued; for example, hair keratinocytes became detectable, aligning with clinical hair regrowth. Many of the transcriptional tissue changes were discernible by the serum proteome, and the treatment response was apparent in rejuvenation of proteome-based organ age. However, treatment was also associated with subclinical proteomic changes reflecting potential side effects of JAK inhibitors, including anemia, weight gain, and hypercoagulability. We expanded the proteome evaluation to 89 additional APECED patients affected by autoimmunity, identifying a patient cluster with the most severe clinical phenotype, highest autoantibody burden, and proteome-based premature aging of multiple organs. These patients had a distinct inflammatory profile, which, in addition to excess IFNγ, was characterized by heightened IL6 responses and TGFβ resistance, partly driven by alterations in sex hormone production. Conclusions Multiomic characterization of treatment response to JAK inhibition uncovers pathogenesis and normalization of tissue-specific autoimmunity. JAK inhibitors are increasingly used to target various immune pathways in inborn errors of immunity, and understanding their complex effects systemically and in the tissues is a prerequisite for safe and successful therapy.
proteins
2026-08-01 | EP231 - ECE_2233 - Autoimmune polyendocrine syndrome type 1 caused by a momozygous aire mutation: report of two siblings
Abstract Introduction APS-1 (Autoimmune Polyendocrine Syndrome type 1) or APECED (Autoimmune Polyendocrinopathy–Candidiasis–Ectodermal Dystrophy) is a rare disease caused by biallelic genetic changes in the AIRE gene. The three most common clinical manifestations are chronic mucocutaneous candidiasis, hypoparathyroidism, and primary adrenal insufficiency (Addison's disease). More than 126 different mutations in the AIRE gene have been described. There is no clear genotype–phenotype correlation. A wide variability in the spectrum and severity of clinical manifestations has been described even among carriers with the same AIRE genetic change, even among siblings. We present the cases of two siblings (an older sister, 20 years old, and a younger brother, 17 years old) with a homozygous loss-of-function mutation in the AIRE gene. Case presentation The older sister was initially diagnosed at 6.5 years old with hypoparathyroidism and at 8 years with primary adrenal insufficiency. At 11 years, she remained at Tanner stage I, and biochemical evaluation revealed primary hypogonadism. She developed onychomycosis at 12 years and was also diagnosed with hypothyroidism at 16 years. The younger brother developed onychomycosis before the age of 9. At 9 years old, he was diagnosed with hypoparathyroidism and Addison's disease. He was also diagnosed with hypothyroidism at 10 years old. At the latest biochemical evaluation, at 17 years old, his gonadotropin levels showed an increasing trend indicative of primary gonadal insufficiency. Genetic testing revealed a homozygous AIRE variant, c.892G > A (p.Glu298Lys) in both siblings, while their parents were found to be heterozygous carriers. Conclusions Despite the well-known poor genotype–phenotype correlation in patients carrying the same pathogenic AIRE variants, herein, we describe two siblings with the same homozygous AIRE mutation who exhibited similar clinical manifestations, albeit with disease onset at different ages. Moreover, in the older sister, a switch from conventional therapy to palopegteriparatide was initiated upon reaching adulthood because of poorly controlled hypoparathyroidism.
2026-08-01 | EP593 - ECE_3589 - Therapeutic challenges of immune checkpoint inhibitor-induced type 1 diabetes within polyendocrinopathy: two case reports
Abstract Immune checkpoint inhibitors (ICIs) are increasingly used, highly effective antineoplastic agents that can induce a broad spectrum of immune-mediated endocrine adverse events involving multiple glands. Among these, hypophysitis, autoimmune thyroiditis and primary adrenal insufficiency are the most frequently reported entities, occurring either in isolation or as part of complex polyendocrinopathies. Development of endocrine toxicities has been associated with improved cancer outcomes, yet autoimmune insulitis with new-onset type 1 diabetes mellitus (T1DM) remains a relatively rare but clinically demanding complication. This abstract presents two patients treated with combined anti-CTLA-4 and anti-PD-1 therapy who developed ICI-induced T1DM as the first immune-mediated endocrine event, followed by additional endocrinopathies, creating major challenges in glycaemic management. The first case is a 52-year-old man with stage IV malignant melanoma treated with ipilimumab plus nivolumab. Before the fourth treatment cycle, routine testing revealed asymptomatic but marked hyperglycaemia without ketoacidosis. Under multiple daily human insulin injections, glycaemic control initially stabilised, allowing ambulatory follow-up. Within one month, he was additionally diagnosed with adrenal insufficiency and hypothyroidism, necessitating glucocorticoid and levothyroxine replacement. Concomitant hormone substitution was accompanied by highly labile glycaemia at home, prompting transition to analogue basal–bolus insulin therapy. On maintenance nivolumab, his melanoma exhibits substantial regression and glucose control is acceptable, although he repeatedly declines insulin pump therapy and continuous glucose monitoring. The second case is a 55-year-old woman with malignant pleural mesothelioma who also received ipilimumab plus nivolumab. Following the second cycle, severe multisystem immune-related toxicity with prominent urticarial manifestations led to discontinuation of immunotherapy. She was subsequently admitted repeatedly for diabetic ketoacidosis and painful oesophageal candidiasis. Under empiric systemic glucocorticoid treatment, glycaemic control proved extremely unstable with frequent hypoglycaemic episodes, which improved after tapering and switching methylprednisolone to hydrocortisone in the absence of clear clinical adrenal insufficiency. Autoimmune thyroiditis with hypothyroidism was diagnosed and treated with levothyroxine, while an ACTH stimulation test off steroids ultimately excluded primary adrenal insufficiency. Because of severely impaired metabolic control (HbA1c 11.6%), she was transitioned to analogue basal–bolus insulin in an inpatient setting, resulting in marked attenuation of glucose excursions and resolution of hypoglycaemia, though further basal insulin titration and planned CGM are required. These cases illustrate that ICI-induced T1DM, particularly when embedded in evolving polyendocrinopathy, demands intensive, dynamically adjusted insulin therapy and close interdisciplinary follow-up to balance oncological benefit and endocrine safety.
2026-08-01 | EP245 - ECE_2602 - Teriparatide as an effective treatment for refractory hypocalcemia in Autoimmune Polyglandular Syndrome Type 1
Abstract Introduction Autoimmune Polyglandular Syndrome Type 1 (APS-1) is a rare inherited disorder characterized by the triad of chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency. Management of hypocalcemia in APS-1 can be challenging, particularly when malabsorption limits oral calcium and active vitamin D efficacy. Teriparatide, a recombinant PTH (1-34) analog, is not approved for hypoparathyroidism but has been used off-label in selected refractory cases. Case report Female, 26-year-old, followed in the Endocrinology Department since age 18 for APS-1, comprising primary adrenal insufficiency, primary hypoparathyroidism, premature ovarian insufficiency, autoimmune hepatitis, ectodermal dystrophy of dental enamel and nails, and exocrine pancreatic insufficiency. She was on calcium, calcitriol, azathioprine, hydrocortisone, fludrocortisone, estradiol, progesterone, and pancreatin. Since 2017, she has experienced recurrent episodes of symptomatic hypocalcemia despite high-dose calcitriol (2,25 µg/day) and calcium carbonate (4500 mg/day), typically triggered by diarrheal exacerbations. She reported a long-standing history of alternating diarrhea and constipation. In 2024, she presented to the Emergency Room with facial and extremities paresthesias and muscle stiffness. One month earlier, she started complaining of nausea, vomiting, and diarrhea, and the subsequent symptomatic hypocalcemia was treated with intravenous calcium gluconate(IV calcium) and increased oral calcium dose. At readmission, biochemical evaluation revealed hypokalemia, hypocalcemia, hypomagnesemia and normal serum phosphorus, and she started IV calcium and electrolyte correction. During the first 15 days of hospitalization, repeated attempts to discontinue IV calcium and maintain oral therapy alone resulted in recurrent severe hypocalcemia. On day 16, teriparatide 20 µg once daily was initiated as an off-label treatment for refractory and severe hypocalcemia. Within two days, IV calcium supplementation was successfully discontinued, and the patient transitioned to oral therapy, with diarrhea resolution. Following discharge, oral calcium carbonate and calcitriol doses were progressively reduced. Ten months later, she remains clinically stable with normal calcium, phosphorus, and calciuria on calcium carbonate 3000 mg/day, calcitriol 1 µg/day, and teriparatide 20 µg every other day. Conclusions This case supports the use of teriparatide as a potential therapeutic option for refractory hypocalcemia due to hypoparathyroidism in APS-1, especially when malabsorption limits conventional therapy. It should be reserved for selected patients under close monitoring. However, the optimal treatment duration remains uncertain, as long-term safety data are still limited.
2026-07-17 | Palopegteriparatide Treatment for Hypoparathyroidism in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy - a Case Series and Literature Update
Abstract Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), also known as autoimmune polyglandular syndrome type 1 (APS-1), is an autosomal recessive disorder of thymic T cell negative selection that results in autoimmune destruction of various endocrine and extra-endocrine tissues. The classic clinical triad of the syndrome includes hypoparathyroidism (hypoPT), chronic mucocutaneous candidiasis (CMC), and adrenal insufficiency, while involvement of thyroid, pancreas, gonads, and ectodermal tissues are also frequently observed. Historically, treatment for hypoPT, the most common endocrine manifestation of APECED, has posed a unique challenge. Conventional therapy with oral calcium and active vitamin D analogues is often complicated by the presence of malabsorption and esophageal disorders, which are prevalent in APECED patients. Moreover, supplementation with oral calcium and active vitamin D analogues without correction of the underlying parathyroid hormone (PTH) insufficiency can result in renal and other soft-tissue calcifications. Short-acting PTH therapies, which have been used off-label in the treatment of hypoPT, fail to mimic normal parathyroid physiology due to their brief half-lives and can result in fluctuations of serum calcium levels between hypocalcemia and hypercalcemia. Long-acting PTH analogues have recently been developed to more closely mimic physiologic PTH activity. One such agent, palopegteriparatide, a prodrug of PTH (1,34), has shown promise to be the first hormone replacement therapy for hypoPT. We report our experience in four patients with APECED-associated hypoPT who initiated treatment with palopegteriparatide and were followed over the subsequent 4-15 month period. We observed a robust calcemic response to treatment during this follow-up window with wide fluctuations in serum calcium during this period of dose titration. These early observations highlight the effectiveness of palopegteriparatide in patients with APECED, enabling the discontinuation of oral calcium and active vitamin D supplements. They also highlight the question of whether etiology-specific differences in responsiveness may influence dose requirements and calcemic stability.
2026-01-01 | Refractory hypoparathyroidism in paediatric autoimmune polyglandular syndrome type 1: successful long-term use of teriparatide
Autoimmune polyglandular syndrome type 1 (APS-1) is a rare monogenic disorder caused by pathogenic variants in the autoimmune regulator (AIRE) gene.It typically manifests in childhood with at least two features of the classic triad: chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency.We present the case of an 11-year-old girl from a consanguineous family, with severe hypocalcaemia and chronic oral candidiasis.Despite high-dose calcium and calcitriol therapy, she experienced recurrent symptomatic hypocalcaemia requiring multiple hospitalisations.Genetic testing confirmed homozygosity for the pathogenic AIRE variant c.967_979del, establishing the diagnosis of APS-1.Due to poor biochemical control, teriparatide (parathyroid hormone, PTH ) was initiated at 20 µg twice daily, leading to rapid improvement in calcium-phosphate homeostasis, a 75% reduction in oral calcium requirements, and no further hospitalisations over a two-year period.The therapy was well tolerated with no adverse events.This is the first paediatric case reported in Colombia using recombinant PTH (1-34) for APS-1-related hypoparathyroidism, supporting its therapeutic role in refractory cases.
antibodies
2026-04-10 | Retinopathy caused by a primary immune regulatory disorder - the spectrum of AIRE-associated retinopathy: case series and literature review.
Retinal involvement in autoimmune polyendocrine syndrome type 1 (APS1), a rare monogenic autoimmune disorder caused by mutations in the AIRE gene, is increasingly recognised but remains poorly defined. Prior reports suggest a variable phenotype, ranging from mild changes to severe vision loss, often presumed untreatable. We explored the range of retinal phenotypes associated with AIRE gene deficiency in a multicentre case series of patients with APS1. We performed a retrospective case note review of patients with molecularly confirmed APS1 from tertiary ophthalmic centres. Clinical history, multimodal retinal imaging, electrophysiology, genetic data, and treatment regimens were analysed. Histopathology was available in one case postmortem. Records were reviewed from five unrelated female patients. Median age was 14 years at onset of ocular involvement and 33 years at most recent follow up. Some findings from two cases have been previously reported. Three distinct pathogenic AIRE variants contributing to biallelic genotypes were observed. Retinal findings ranged from structurally and functionally normal to advanced degeneration. One patient demonstrated sharp zonal atrophy on histopathology. Inflammatory features predominated in two cases, both showing durable vision preservation with periocular or systemic immunomodulation. One patient demonstrated four years of disease stabilisation with rituximab. No consistent genotype-phenotype correlation emerged. AIRE-associated retinopathy encompasses a diverse spectrum, from clinically silent to profound degeneration. Early, targeted immunomodulation might preserve vision in selected cases. These findings advocate for ophthalmic surveillance in APS1, and support further investigation into predictive biomarkers and possible tailored immunotherapy in this vision-threatening autoimmune disorder.
2026-02-07 | Pediatric IPEX-Associated Dermatitis Responds To Dupilumab: Evidence from Skin Transcriptomics and Immune Profiling.
Immunodysregulation, Polyendocrinopathy, Enteropathy, and X-linked (IPEX) syndrome is a rare autoimmune disorder caused by mutations in the FOXP3 gene. Patients with IPEX frequently present with severe dermatitis, diabetes, and enteropathy. This study explores the efficacy of Dupilumab (an anti-IL-4Rα monoclonal antibody) in treating persistent, severe dermatitis in an IPEX patient refractory to conventional treatments like sirolimus. We conducted a clinical case study of a 2-year-old IPEX patient with refractory dermatitis. Whole-exome sequencing (WES) confirmed the FOXP3 mutation. Skin biopsies were analyzed for inflammatory gene expression by RNA sequencing and immunohistochemistry to characterize inflammatory pathways. Immune cell phenotyping was performed using flow cytometry pre- and post-treatment in peripheral blood mononuclear cells (PBMCs). The patient was treated with Dupilumab alongside sirolimus and prednisone. Clinical improvements were evaluated using the Eczema Area and Severity Index (EASI) score. Immunohistochemistry revealed elevated IL-13 expression. RNA sequencing of skin samples revealed upregulation of both Th1- and Th2-related genes, suggesting a dual inflammatory phenotype in IPEX dermatitis. The patient exhibited significant clinical improvement after 8 months of sustained Dupilumab therapy, with the EASI decreasing from 24.8 to 0.4. Flow cytometry demonstrated a reduction in Th1 and Th2 cell subsets post-treatment, accompanied by an increase in Treg and Th3 cell populations as well as enhanced expression of immunosuppressive markers such as CTLA-4 and CD39. Dupilumab appears promising as a therapeutic option for managing refractory dermatitis in IPEX, particularly by attenuating Th1/Th2 inflammation and promoting regulatory responses mediated by Treg and Th3 cells.
2025-12-22 | CARD8: An Emerging Genetic Cause of Autoinflammatory and CVID-Like Syndromes?
Introduction CARD8 encodes the caspase recruitment domain-containing protein 8, a negative regulator of the NLRP3 inflammasome and a modulator of innate immune signaling. Although not yet formally classified among inborn errors of immunity (IEIs), emerging evidence suggests a potential role of CARD8 variants in autoinflammatory syndromes and immune dysregulation. Case Presentations We describe three unrelated patients from different families with variable phenotypes involving autoinflammation and immune dysregulation. Patient 1: A 15-year-old female with an IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked)-like phenotype, including alopecia universalis, growth retardation, pubertal delay, and elevated serum IL-18 levels. A heterozygous frameshift variant in CARD8 (c.40delG, p.Glu14fs) was identified. Patient 2: A 3-year-old male presenting with neonatal lupus-like rash, severe atopic dermatitis, refractory autoimmune cytopenias, persistent hepatitis, and total villous atrophy on intestinal biopsy (Marsh 3b). A heterozygous frameshift variant (c.68dupG, p.Ser24fs) was detected. Patient 3: A 42-year-old female with adult-onset CVID (common variable immunodeficiency)-like phenotype, including recurrent pneumonia, chronic diarrhea, and persistent hypogammaglobulinemia requiring immunoglobulin replacement. A heterozygous missense variant (c.1093A>C, p.Met365Leu) was identified. Discussion These cases illustrate the broad clinical spectrum associated with CARD8 variants, ranging from severe early-onset autoinflammatory disease to adult-onset humoral immunodeficiency. The presence of elevated IL-18 and multi-organ involvement supports dysregulated inflammasome activation as a key pathogenic mechanism. Importantly, heterozygous variants may result in incomplete penetrance and variable expressivity, complicating diagnosis and counseling. Conclusion CARD8 mutations should be considered in patients presenting with unexplained autoinflammation, immune dysregulation, or CVID-like phenotypes. Recognition of this spectrum may facilitate earlier diagnosis, appropriate therapeutic interventions targeting IL-1/IL-18 pathways, and genetic counseling for affected families.
2025-11-12 | Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1.
Autoimmune polyendocrine syndrome type 1 (APS-1) is a rare, monogenic autoimmune disorder that may manifest as type 1 diabetes (T1D). Teplizumab, an anti-CD3 monoclonal antibody, delays progression of stage 2 T1D, but its effects in APS-1-associated diabetes are unknown. We report clinical responses of two adolescents with APS-1 and stage 2 T1D who received 14-day courses of teplizumab. In one patient, pancreatic MRI and spectral immune cell phenotyping were performed before and after treatment. Both patients exhibited improved glycemia. One who briefly required insulin recovered insulin independence 2 weeks after therapy. Pancreatic volume transiently increased, and circulating lymphocytes showed changes in homing receptors and senescence markers in the individual who underwent those studies. Nonpancreatic APS-1 manifestations were unchanged. Teplizumab may preserve β-cell function in APS-1-associated T1D. Larger studies are needed to define efficacy, durability, and immunologic and tissue mechanisms in this rare context.
2025-11-01 | First-in-class anti-human CD45RC antibody targets CD45RChigh T and B cells to mitigate pathogenic immune responses.
CD45RC, an isoform of the transmembrane tyrosine phosphatase CD45, regulates T and B cell antigen receptor signaling and is highly expressed on Th1 precursors, Th1 cells, T effector memory CD45RA+ cells, and most B cells. Preclinical studies have shown that anti-CD45RC monoclonal antibodies (mAbs) can prevent or control diseases such as transplant rejection, graft-versus-host disease (GvHD), Duchenne muscular dystrophy (DMD), and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED or APS-1). However, their mechanism of action remained unclear. Here, we elucidate the mechanism of anti-human CD45RC mAbs, showing that it selectively induces apoptosis in CD45RChigh T and B cells through binding to cells expressing >24 CD45RC molecules/μm2. This interaction triggers intracellular signaling without cytokine release. Cytotoxicity by apoptosis is enhanced by crosslinking with a secondary antibody. The mAb also promotes antibody-dependent cellular phagocytosis by monocyte-derived macrophages, without inducing antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, likely due to the length of CD45RC. In CD34+-humanized NSG mice, anti-CD45RC mAbs demonstrated dose-dependent depletion of CD45RChigh T and B cells and defined a minimum effective dose to prevent xenogeneic GvHD. These findings define the mechanism of action of this first-in-class anti-human CD45RC therapeutic mAb and supports its potential for the treatment of transplant rejection, GvHD, and autoimmune diseases.
cell therapies
2026-09-07 | Distinguishing clinical features of paediatric autoimmune Addison's disease and polyendocrine syndromes: a 15-year single-centre observational study from Baghdad, Iraq.
Autoimmune Addison's disease (AAD) is a rare endocrine disorder characterised by immune-mediated destruction of the adrenal cortex. AAD may occur in isolation or as part of a broader autoimmune polyendocrine syndrome (APS). Distinguishing the two is essential owing to implications for patient screening and prognosis. Earlier identification of APS patients is crucial for preserving residual adrenal function and developing future targeted therapies. This study aimed to define clinical and laboratory features of paediatric isolated AAD and APS. This retrospective cohort study recruited 55 paediatric patients; 27/55 had isolated AAD and 28/55 had APS. They were followed at the Children's Welfare Teaching Hospital, Baghdad, Iraq, between 2009 and 2024. Data collected and compared included: demographic variables (age, gender, family history, duration of symptoms), presenting clinical features and adrenal crisis, and laboratory parameters. Male predominance was observed in both groups, although the difference was not significant. Positive family history was more frequent in APS (p = 0.03). Clinically, hyperpigmentation, weight loss, poor appetite, and hypoglycaemia-induced seizures were significantly higher in isolated AAD (p = 0.0001, 0.0002, 0.042, 0.041). Adrenal crises were more frequent in APS cases (p = 0.18). Major risk factors for adrenal crisis included poor treatment compliance and infections. Laboratory parameters showed that hyperkalaemia and hypoglycaemia were significantly more pronounced in AAD (0.0079 and 0.00002). Distinguishing isolated AAD from APS may be clinically useful. Differences were observed in metabolic severity, family history, weight loss, hyperpigmentation, and risk of adrenal crisis. These findings suggest that management of both conditions may benefit from a tailored approach, emphasizing treatment adherence and infection prevention in both groups.
2026-08-16 | FOXP3 as a therapeutic target in autoimmune diseases: Molecular regulation, regulatory T cells, and emerging precision immunotherapies
Forkhead box protein P3 (FOXP3) is a key transcription factor responsible for the development and function of regulatory T cells (Tregs), which play a crucial role in maintaining immune tolerance and preventing autoimmune responses. Defects in FOXP3 expression or function can impair Treg activity, leading to immune dysregulation and the development of autoimmune diseases. While complete loss of FOXP3 results in immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, altered FOXP3 expression and Treg dysfunction have also been reported in common autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes mellitus, multiple sclerosis, and inflammatory bowel disease. Recent advances have significantly improved our understanding of the molecular mechanisms regulating FOXP3, including transcriptional control, epigenetic modifications, metabolic pathways, and environmental influences that affect Treg stability and function. These discoveries have led to the development of novel therapeutic approaches aimed at restoring immune tolerance through enhancement of FOXP3 activity and Treg-mediated suppression. Strategies such as low-dose interleukin-2 therapy, adoptive Treg cell transfer, antigen-specific Treg therapy, chimeric antigen receptor regulatory T cells (CAR-Tregs), and gene-editing technologies have shown promising results in preclinical and early clinical studies. This review summarizes the current understanding of FOXP3 biology, its role in autoimmune disease pathogenesis, and recent advances in FOXP3-directed therapeutic strategies. In addition, emerging concepts including Treg plasticity, epigenetic regulation, immunometabolism, and precision immunotherapy are discussed. A better understanding of FOXP3-mediated immune regulation may facilitate the development of targeted therapies capable of achieving long-term immune tolerance and improved clinical outcomes in patients with autoimmune diseases.
2026-06-26 | FOXP3 Mutations and Instability as Determinants of Regulatory T-Cell Plasticity in Endocrine Autoimmunity
Autoimmune endocrine diseases constitute a group of disorders characterized by immune-mediated destruction or dysfunction of hormone-producing glands. The pathogenesis of these diseases reflects a breakdown of immune tolerance in which regulatory T cells (Tregs) play a key role. The transcription factor forkhead box P3 (FOXP3) is a master regulator of Treg differentiation and suppressive function. Also, it is central to maintaining self-tolerance. Genetic mutations in FOXP3, including those responsible for immune dysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) syndrome, highlight the critical role of FOXP3 in endocrine immune tolerance. Emerging evidence suggests that autoimmune endocrine disorders may reflect organ-specific destabilization of FOXP3 expression rather than complete Treg deficiency. The reversibility or irreversible loss of FOXP3 gene expression represents a key determinant of Treg plasticity and the persistence of autoimmune inflammation. This review proposes an integrated genetic–epigenetic model of FOXP3 instability and examines how the endocrine microenvironment shapes Treg plasticity. Genetic or epigenetic alterations affecting FOXP3 expression can impair Treg activity and precipitate endocrine organ-specific autoimmunity. Epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNA-mediated regulation that modulate FOXP3 transcriptional activity are discussed. From a translational perspective, the potential of FOXP3 as a biomarker for endocrine disease susceptibility and progression was summarized. Furthermore, therapeutic strategies employed for expanding or engineering functional FOXP3+ Tregs using antigen-specific vaccines, chimeric antigen receptors (CAR)-Tregs, gene therapy, or low-dose interleukin-2 (IL-2) were described.
2026-05-01 | Human FOXP3 Isoforms in Health and Disease
Forkhead box P3 (FOXP3) is the master transcription factor of regulatory T cells (Tregs) and is essential for maintaining immune tolerance. FOXP3 is stably expressed in Tregs, driving their suppressive function, and it is transiently induced in conventional T cells (Tconv) upon activation, where it fine-tunes immune responses. In humans, but not in mice, FOXP3 is expressed as two major isoforms: the full-length protein (FOXP3FL) and an isoform lacking exon 2 (FOXP3Δ2), with additional variants such as FOXP3Δ7 and FOXP3Δ2Δ7 described. The precise contribution of each isoform to Treg development, stability, and function in health and disease remains incompletely defined, although clinical observations indicate that patients expressing only FOXP3Δ2 develop autoimmunity, highlighting a nonredundant role for FOXP3FL in Treg-mediated tolerance. Multiple studies have further associated increased FOXP3Δ2 expression with autoimmune disease and reduced Treg stability, suggesting that the relative abundance of FOXP3FL and FOXP3Δ2 may critically shape Treg function and the balance between tolerance and pathology. However, the physiological expression levels and ratios of FOXP3FL and FOXP3Δ2 in Tregs and activated Tconvs remain poorly characterized, hindering understanding of the distinct functions of these isoforms, the correlation of specific FOXP3 mutations with isoform expression patterns and disease severity, and the development of Treg-targeted and gene transfer–based therapies. To address this, we quantified isoform-specific expression in Tregs and activated Tconvs from healthy donors and in patients with loss-of-function mutations in FOXP3 that cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, a severe monogenic disorder that typically presents in early infancy, affects male patients, and is almost uniformly fatal without definitive therapy. Our data indicate that FOXP3Δ2 is the dominant isoform in activated Tconvs and Tregs across both cohorts, with a FOXP3FL:FOXP3Δ2 ratio of 0.52 ± 0.08, suggesting that regulated co-expression of FOXP3 isoforms but not exclusive expression of a single isoform underpins effective Treg development and function. Consequently, therapeutic strategies for IPEX and autoimmunity should aim to restore a physiologic FOXP3 isoform balance rather than solely achieving full-length FOXP3 expression.
2026-03-15 | Preclinical efficacy and safety assessment of engineered regulatory T cells for treatment of IPEX and other autoimmune disorders.
FOXP3 is an essential transcription factor driving lineage commitment and function of regulatory T cells (Tregs). We previously reported a proof-of-concept study describing engineered Tregs (EngTregs) generated using homology-directed repair-based editing of the FOXP3 gene in CD4+ T cells, resulting in constitutive, high-level endogenous FOXP3 expression leading to acquisition of a Treg phenotype and robust in vitro and in vivo suppressive function. Here, we expand this gene-editing strategy to integrate a functional FOXP3 cDNA to enable EngTreg therapy for immune dysregulation, poly-endocrinopathy, enteropathy, X-linked syndrome (IPEX), a devastating multiorgan autoimmune disorder mediated by mutations within the FOXP3 gene. We provide a detailed characterization of preclinical EngTreg generation, including gene targeting efficiencies, cell enrichment and expansion, analyses of potential off-target editing, and phenotypic and functional characterization, including in vitro suppression of effector T cells and in vivo reversal of graft-versus-host disease. Importantly, in parallel, we utilize syngeneic and humanized mouse models to demonstrate the safety of EngTregs in primary and secondary humoral responses and viral infection control, respectively. Our combined preclinical dataset strongly supports the efficacy and safety of EngTregs as a promising potential cellular therapeutic approach for IPEX and possibly other autoimmune disorders.
other
2025-08-14 | Precision T cell correction platform for inborn errors of immunity.
CRISPR-Cas9 gene editing is a promising tool to correct pathogenic variants for autologous cell therapies targeting inborn errors of immunity (IEI). Current strategies, such as gene knockout or cDNA knockin, address many single-gene defects but can disrupt gene expression, highlighting the need for precise correction platforms. While transplanting corrected autologous hematopoietic stem cells is a curative approach, it is unsuitable for patients with advanced disease, inflammation, or acute infections. As correcting T cells is an alternative therapeutic strategy for lymphoid IEIs, we present an efficient T cell single-nucleotide variant (SNV) correction platform based on homology-directed repair (HDR). By using STAT1 gain-of-function, cartilage hair hypoplasia, deficiency of ADA2, and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy as IEI models, we demonstrate that our platform achieves up to 80% correction, with resultant functional correction of the disease phenotype in the selected models. Furthermore, we performed safety profiling using GUIDE-seq, single-cell RNA sequencing, long-read genome sequencing, and proteomics analysis and detected no genomic, transcriptomic, or proteomic aberrations. This study establishes HDR-based SNV editing as a portable method for developing clinical autologous T cell therapies and represents a promising step toward a broad-spectrum gene correction platform for treating diverse monogenic immune disorders.
2025-03-12 | The CRISPR-Cas9 System Is Used to Edit the Autoimmune Regulator Gene in Vitro and in Vivo.
Although mutations in the AIRE gene in patients with autoimmune polyendocrine syndrome type 1 (APS-1) syndrome are associated with the onset of this autoimmune disease, much of what is known about its mechanisms has been obtained through studies with Aire mutant Mus musculus mouse model or with Aire mutant medullary thymic epithelial cells (mTEC) cultured in vitro. The in vivo murine model was soon established, and ten mutant strains are currently described. Most Aire mutant mice were obtained through homologous recombination, which generated Aire knockout (KO) animals. Nevertheless, long-term cultures of mTECs from APS-1 patients or Aire mutant mice are difficult to establish. The CRISPR-Cas9 system to edit Aire in a murine mTEC line in vitro and mouse embryo has been successfully used to overcome this. The ribonucleoprotein (RNP) complexes composed of the guide RNA (gRNA), the Cas9 enzyme, and single-stranded oligonucleotides (ssODN) were designed to target Aire exons 6 and 8 separately. The CRISPR-Cas9 makes it possible to produce NHEJ-derived indels or HDR-derived mutations. Efforts are being concentrated on using RNP complex rather than plasmid vectors, as RNP makes recurrent NHEJ-derived mutations among in vitro and in vivo editions. One recurrent mutation was described in the Aire exon 6 (del 3554G) and the other in the exon 8 (del 5676_5677TG), i.e., the exon 6 mutation was kept in an mTEC clone edited in vitro and in vivo in a mouse, and the exon 8 mutation was kept in several mTEC clones in vitro. In contrast, none of the mutations obtained with the nickase system (plasmid expression vector) were recurrent, indicating the participation of the RNP complex in recurring mutation, which offers advantages, as it does not involve recombinant plasmids and does not generate a genetically modified organism but rather a mutant animal or cell.
2024-10-25 | Uncovering ASO-Targetable Deep Intronic AIRE Variants: Insights and Therapeutic Implications.
High-throughput DNA sequencing has accelerated the discovery of disease-causing genetic variants, yet only in 10-40% of cases yield a genetic diagnosis. Increased implementation of genome sequencing has enabled a deeper exploration of the noncoding genome and recognition of noncoding variants as major contributors to disease. In a recent study, we identified a deep intronic variant in the AutoImmune REgulator (AIRE) gene (c.1504-818 G>A) as the cause of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), a life-threatening monogenic autoimmune disorder most often caused by biallelic AIRE defects. This deep intronic variant disrupts normal splicing AIRE , causing pseudoexon inclusion and altered protein function. By developing an antisense oligonucleotide (ASO) targeting the pseudoexon sequence, we restored normal AIRE transcript in vitro, thereby revealing a potential genotype-specific candidate treatment. Our study illustrates key aspects of intronic variant detection, validation, and candidate ASO development. Herein, we briefly highlight the growing potential of ASO-based therapies for deep intronic variants, addressing the unmet need of personalized, genotype-specific therapies in diseases lacking curative options.
2024-09-18 | A deep intronic splice-altering AIRE variant causes APECED syndrome through antisense oligonucleotide-targetable pseudoexon inclusion.
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a life-threatening monogenic autoimmune disorder primarily caused by biallelic deleterious variants in the autoimmune regulator (AIRE) gene. We prospectively evaluated 104 patients with clinically diagnosed APECED syndrome and identified 17 patients (16%) from 14 kindreds lacking biallelic AIRE variants in exons or flanking intronic regions; 15 had Puerto Rican ancestry. Through whole-genome sequencing, we identified a deep intronic AIRE variant (c.1504-818 G>A) cosegregating with the disease in all 17 patients. We developed a culture system of AIRE-expressing primary patient monocyte-derived dendritic cells and demonstrated that c.1504-818 G>A creates a cryptic splice site and activates inclusion of a 109-base pair frame-shifting pseudoexon. We also found low-level AIRE expression in patient-derived lymphoblastoid cell lines (LCLs) and confirmed pseudoexon inclusion in independent extrathymic AIRE-expressing cell lines. Through protein modeling and transcriptomic analyses of AIRE-transfected human embryonic kidney 293 and thymic epithelial cell 4D6 cells, we showed that this variant alters the carboxyl terminus of the AIRE protein, abrogating its function. Last, we developed an antisense oligonucleotide (ASO) that reversed pseudoexon inclusion and restored the normal AIRE transcript sequence in LCLs. Thus, our findings revealed c.1504-818 G>A as a founder APECED-causing AIRE variant in the Puerto Rican population and uncovered pseudoexon inclusion as an ASO-reversible genetic mechanism underlying APECED.
2024-09-06 | T cell correction pipeline for Inborn Errors of Immunity
CRISPR/Cas9 gene editing technology is a promising tool for correcting pathogenic variants for autologous cell therapies for Inborn Errors of Immunity (IEI). The present IEI correction strategies mainly focus on the knock-in of therapeutic cDNAs, or knockout of the disease-causing gene when feasible. These strategies address many single-gene defects but may disrupt gene expression and require significant optimization for each newly discovered IEI-causing gene, highlighting the need for complementary platforms that can precisely correct diverse pathogenic variants. Here, we present a safe and efficient T cell single nucleotide variant (SNV) correction pipeline based on homology-directed repair (HDR), suitable for diverse monogenic mutations. By using founder mutations of Deficiency of ADA2 (DADA2), Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and Cartilage Hair Hypoplasia (CHH) as IEI models, we show that our pipeline can achieve up to 80% bi-allelic editing, with resultant functional correction of the disease phenotype in patient T cells. We do not find detectable pre-malignant off-target effects or karyotypic, transcriptomic or proteomic aberrations upon profiling patient T cells with GUIDE-seq, single cell RNA sequencing, PacBio based long-read whole genome sequencing, and high-throughput proteomics. This study demonstrates that HDR-based SNV editing is a safe and effective option for IEI T cell correction and that it could be developed to an autologous T cell therapy, as the presented protocol is scalable for a GMP-compatible workflow. This study is a step towards the development of gene correction platform that targets a broad number of monogenic mutations.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.